), a leader in non-invasive monitoring technology for patient care,
recently revealed that its Pronto-7 offering has been awarded a
GOLD Stevie American Business Award. The Pronto-7 received
recognition for the best new service or product in the domain of
Health and Pharmaceuticals. Since its launch in 2011, the acclaimed
Pronto-7 has won four industry awards.
COVIDIEN PLC (COV): Free Stock Analysis Report
MASIMO CORP (MASI): Free Stock Analysis Report
To read this article on Zacks.com click here.
The Pronto-7 is a small device intended for hassle-free and
not-invasive total hemoglobin monitoring in conjunction with
perfusion index, SpO2 and pulse rate. The flyweight Pronto-7
provides reading of total hemoglobin in less than 60 seconds
without causing the pain associated with needles.
The Stevie awards were conceived to build public appreciation of
the achievements of corporate citizens around the globe. Its
purpose is to create recognition of outstanding persons and
entities in the business fraternity, the media and among the
Earlier, in the second quarter of 2012, Masimo completed the
strategic acquisition of PHASEIN AB of Sweden. The purchase price
was $30 million. PHASEIN is a provider of sidestream and mainstream
capnography offerings. It had sales of about $10 million.
This acquisition provides the company with another set of
measurable variables using its know-how. It is expected that
earnings per share will be neutral in 2013 and subsequently turn
Masimo is a market leader in the pulse oximetry monitoring
equipment industry. The company's prospects are encouraging, given
the sizeable global market opportunity, adoption of pulse oximetry
in non-critical areas of the hospital and growing barriers to entry
due to additional non-invasive parameters.
Shipments have been growing at a steady rate fueled by new
contracts. However, the renewal of the royalty agreement with
) provides little or no benefit due to lower rates. Further,
competition is intense and Masimo partly depends upon its OEM
partners for sales. Our Neutral recommendation is supported by a
short-term Zacks #3 Rank (Hold).